Neoadjuvant therapy for locally advanced oral cavity cancer
10.12354/j.issn.1000-8179.2024.20240320
- VernacularTitle:局部晚期口腔癌的新辅助治疗
- Author:
Xue LIQIONG
1
;
Guo YE
Author Information
1. 同济大学附属东方医院肿瘤科(上海市 200123)
- Keywords:
oral cavity cancer;
neoadjuvant therapy;
immunotherapy;
pathological response
- From:
Chinese Journal of Clinical Oncology
2024;51(19):988-992
- CountryChina
- Language:Chinese
-
Abstract:
Oral cavity cancer is the most common type of head and neck squamous cell carcinoma,and patients with locally advanced can-cer are mainly treated via surgical resection,followed by adjuvant radiotherapy.However,over the past decade,therapeutic progress in loc-ally advanced oral cavity cancer has been limited,with the overall survival remaining below 50%.Although many studies have reported high tumor response rates with neoadjuvant chemotherapy and targeted therapy,these findings have not translated into enhanced patient sur-vival.Neoadjuvant immunotherapy has become a research hotspot owing to the success of immunotherapy with immune checkpoint inhib-itors for relapsed and metastatic head and neck squamous cell carcinoma cases,with many ongoing randomized controlled studies focusing on drug discovery.In this review,we discuss the relevant clinical studies and highlight the therapeutic advancements in neoadjuvant immun-otherapy for locally advanced oral cavity cancer.
